Imugene (ASX: $IMU) presents promising cancer immunotherapy data at AACR annual meeting

Imugene Limited (ASX: $IMU) presented encouraging data on its oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA. The preliminary results demonstrate the potential of VAXINIA and HER-Vaxx in providing new treatment options for advanced cancer patients, as discussed by Daneng Li, M.D., and Imugene's Managing Director & CEO Leslie Chong.

Expert and CEO insights on Imugene's cancer immunotherapy advancements

Daneng Li, M.D., commented, 'The results show that our novel oncolytic virus - both alone or in combination with immunotherapy - has the ability to control various cancer types previously resistant to other treatment options, and these early results provide patients with hope of a new treatment option for cancers refractory to standard treatment.' Leslie Chong, Imugene's Managing Director & CEO, stated, 'Preliminary data from the MAST trial demonstrates encouraging anti-tumour activity with our oncolytic virus CF33-hNIS (VAXINIA). Notably, one patient with cholangiocarcinoma achieved an immunological complete response (CR), meaning the disappearance of all signs of their cancer after treatment with VAXINIA, with no known recurrence after one year.'

Summary of Imugene's cancer immunotherapy advancements

Imugene Limited (ASX: $IMU) showcased promising data on its oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Annual Meeting 2024. The results indicate encouraging anti-tumour activity and an overall survival benefit in advanced cancer patients. The company's oncolytic virus CF33-hNIS (VAXINIA) demonstrated the ability to control various cancer types previously resistant to standard treatment, with one patient achieving an immunological complete response. Additionally, the B cell immunotherapy HER-Vaxx induced high levels of HER2-specific antibodies, correlating with tumour reduction. Imugene's vision is to transform and improve cancer treatment, and the presented data at the AACR Annual Meeting 2024 aligns with this goal, offering hope for new treatment options in cancer immunotherapy.